These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 26179129)

  • 1. Turning Regenerative Medicine Breakthrough Ideas and Innovations into Commercial Products.
    Bayon Y; Vertès AA; Ronfard V; Culme-Seymour E; Mason C; Stroemer P; Najimi M; Sokal E; Wilson C; Barone J; Aras R; Chiesi A
    Tissue Eng Part B Rev; 2015 Dec; 21(6):560-71. PubMed ID: 26179129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry.
    Bertram TA; Tentoff E; Johnson PC; Tawil B; Van Dyke M; Hellman KB
    Tissue Eng Part A; 2012 Nov; 18(21-22):2187-94. PubMed ID: 22838399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translating cell-based regenerative medicines from research to successful products: challenges and solutions.
    Bayon Y; Vertès AA; Ronfard V; Egloff M; Snykers S; Salinas GF; Thomas R; Girling A; Lilford R; Clermont G; Kemp P
    Tissue Eng Part B Rev; 2014 Aug; 20(4):246-56. PubMed ID: 24754565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How Regenerative Medicine Stakeholders Adapt to Ever-Changing Technology and Regulatory Challenges? Snapshots from the World TERMIS Industry Symposium (September 10, 2015, Boston).
    Bayon Y; Van Dyke M; Buelher R; Tubo R; Bertram T; Malfroy-Camine B; Rathman M; Ronfard V
    Tissue Eng Part B Rev; 2017 Apr; 23(2):159-162. PubMed ID: 27771996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regenerative Medicine Venturing at the University-Industry Boundary: Implications for Institutions, Entrepreneurs, and Industry.
    Bock AJ; Johnson D
    Adv Exp Med Biol; 2018; 1098():213-236. PubMed ID: 30238374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hurdles in tissue engineering/regenerative medicine product commercialization: a survey of North American academia and industry.
    Johnson PC; Bertram TA; Tawil B; Hellman KB
    Tissue Eng Part A; 2011 Jan; 17(1-2):5-15. PubMed ID: 20726816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Netherlands advancing to the forefront of regenerative medicine.
    Gielen K
    Stem Cells Dev; 2014 Dec; 23 Suppl 1():29-31. PubMed ID: 25457958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing Tissue Engineering and Regenerative Medicine Product Commercialization: The Role of Science in Regulatory Decision-Making for the TE/RM Product Development.
    Bertram TA; Johnson PC; Tawil BJ; Van Dyke M; Hellman KB
    Tissue Eng Part A; 2015 Oct; 21(19-20):2476-9. PubMed ID: 26222734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue engineering and regenerative medicine: manufacturing challenges.
    Williams DJ; Sebastine IM
    IEE Proc Nanobiotechnol; 2005 Dec; 152(6):207-10. PubMed ID: 16441181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects of Advanced Therapy Medicinal Products-Based Therapies in Regenerative Dentistry: Current Status, Comparison with Global Trends in Medicine, and Future Perspectives.
    Bakopoulou A
    J Endod; 2020 Sep; 46(9S):S175-S188. PubMed ID: 32950189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regenerative medicine. The industry comes of age.
    Mason C
    Med Device Technol; 2007; 18(2):25-30. PubMed ID: 17494498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regenerative medicine, resource and regulation: lessons learned from the remedi project.
    Ginty PJ; Rayment EA; Hourd P; Williams DJ
    Regen Med; 2011 Mar; 6(2):241-53. PubMed ID: 21391857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reimbursement and adoption of advanced therapies: the 5-C framework.
    Malik NN
    Regen Med; 2014; 9(5):573-8. PubMed ID: 25372076
    [No Abstract]   [Full Text] [Related]  

  • 14. [Social effects in regenerative medicine].
    Miyake J
    Nihon Rinsho; 2008 May; 66(5):1004-12. PubMed ID: 18464524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Great expectations: private sector activity in tissue engineering, regenerative medicine, and stem cell therapeutics.
    Lysaght MJ; Jaklenec A; Deweerd E
    Tissue Eng Part A; 2008 Feb; 14(2):305-15. PubMed ID: 18333783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory enablers and regulatory challenges for the development of tissue-engineered products in the EU.
    Brévignon-Dodin L
    Biomed Mater Eng; 2010; 20(3):121-6. PubMed ID: 20930319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Manufacturing road map for tissue engineering and regenerative medicine technologies.
    Hunsberger J; Harrysson O; Shirwaiker R; Starly B; Wysk R; Cohen P; Allickson J; Yoo J; Atala A
    Stem Cells Transl Med; 2015 Feb; 4(2):130-5. PubMed ID: 25575525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring innovation in stem cell and regenerative medicine in Japan: the power of the consortium-based approach.
    Munisi HI; Xie Z; Sengoku S
    Regen Med; 2014; 9(4):467-77. PubMed ID: 25159064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regenerative medicine and the developing world.
    Greenwood HL; Singer PA; Downey GP; Martin DK; Thorsteinsdóttir H; Daar AS
    PLoS Med; 2006 Sep; 3(9):e381. PubMed ID: 16968130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue engineering/regenerative medicine ventures should invest early in market research to understand the future market's needs.
    Gemmiti C
    Tissue Eng Part B Rev; 2013 Apr; 19(2):97-8. PubMed ID: 23327734
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.